Anakinra for COVID-19 Respiratory Symptoms (ANACONDA)
Efficacy and Safety of ANAkinra During Adult COVID-19 With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial
Sponsor: INSERM CIC-P 1415, University Hospital Center of Tours
Terminated
Efficiency and safety reasons
Listed as NCT04364009, this PHASE3 trial focuses on ANAKINRA Treatment and COVID-19 Infection and remains terminated or withdrawn. Sponsored by INSERM CIC-P 1415, University Hospital Center of Tours, it has been updated 9 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Feb 2021 — Oct 2021 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Suspended PHASE3
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Suspended PHASE3
Status: Recruiting → Suspended
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Oct 2020 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- INSERM CIC-P 1415, University Hospital Center of Tours
- Swedish Orphan Biovitrum
- University Hospital, Tours
For direct contact, visit the study record on ClinicalTrials.gov .